Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 86 entries
View as:

International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03269565 Org: User:
Start: 08/31/17 End: 01/31/21 Due: 01/31/22

A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries

Phase: N/A Priority: Normal
NCT ID: NCT02368314 Org: User:
Start: 01/31/15 End: 12/31/15 Due: 12/31/16

Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT04056897 Org: User:
Start: 06/07/19 End: 01/12/22 Due: 01/12/23

A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT05800327 Org: User:
Start: 12/07/22 End: 12/31/27 Due: 12/31/28

Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis

Phase: N/A Priority: Normal
NCT ID: NCT02762812 Org: User:
Start: 01/31/16 End: 07/31/17 Due: 07/31/18

Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)

Phase: N/A Priority: Normal
NCT ID: NCT03288870 Org: User:
Start: 09/19/17 End: 08/10/21 Due: 08/10/22

Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT02036723 Org: User:
Start: - End: - Due: -

Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)

Phase: N/A Priority: Normal
NCT ID: NCT05747261 Org: User:
Start: 02/02/23 End: 08/31/30 Due: 08/31/31

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)

Phase: N/A Priority: Normal
NCT ID: NCT03912402 Org: User:
Start: 12/25/18 End: 07/07/20 Due: 07/07/21

Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)

Phase: N/A Priority: Normal
NCT ID: NCT05037188 Org: User:
Start: 08/10/21 End: 04/18/22 Due: 04/18/23

Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05986331 Org: User:
Start: 07/18/22 End: 12/31/24 Due: 12/31/25

Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis

Phase: N/A Priority: Normal
NCT ID: NCT03476993 Org: User:
Start: 04/27/18 End: 07/01/19 Due: 07/01/20

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05751928 Org: User:
Start: 04/05/23 End: 06/30/27 Due: 06/30/28

Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT02753088 Org: User:
Start: 10/31/13 End: 11/30/15 Due: 11/30/16

An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURN

Phase: N/A Priority: Normal
NCT ID: NCT06987864 Org: User:
Start: 04/13/20 End: 11/02/22 Due: 11/02/23

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05739006 Org: User:
Start: 02/08/21 End: 08/31/23 Due: 08/31/24

Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®

Phase: N/A Priority: Normal
NCT ID: NCT04027803 Org: User:
Start: 09/21/18 End: 04/07/19 Due: 04/07/20

First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03912441 Org: User:
Start: 01/30/19 End: 09/30/19 Due: 09/30/20

Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT06640517 Org: User:
Start: 08/08/24 End: 02/29/28 Due: 02/28/29

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06668792 Org: User:
Start: 12/26/24 End: 07/31/28 Due: 07/31/29

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05732805 Org: User:
Start: 08/02/22 End: 07/31/25 Due: 07/31/26

First-in-human Study of Safety, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-089 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03103438 Org: User:
Start: 11/30/16 End: 05/31/17 Due: 05/31/18

First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02380287 Org: User:
Start: 03/31/15 End: 10/31/15 Due: 10/31/16

International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis

Phase: N/A Priority: Normal
NCT ID: NCT03447704 Org: User:
Start: 02/09/18 End: 04/05/23 Due: 04/05/24

An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT05385744 Org: User:
Start: 04/05/21 End: 09/29/23 Due: 09/29/24